Male Breast Cancer
80
1
1
57
Key Insights
Highlights
Success Rate
79% trial completion
Published Results
29 trials with published results (36%)
Research Maturity
57 completed trials (71% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 59/100
18.8%
15 terminated out of 80 trials
79.2%
-7.3% vs benchmark
1%
1 trials in Phase 3/4
51%
29 of 57 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 57 completed trials
Clinical Trials (80)
ETHAN - ET for Male BC
Male breAsT cAncer preDisposition Factor: Creation of a Control Cohort 2
EORTC Quality of Life Measurement in Males With Breast Cancer
Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast Cancer
Testosterone & Tamoxifen Trial
Hypofractionated Image Guided Radiation Therapy in Treating Patients With Stage IV Breast Cancer
Finasteride (MK-0906) and Male Breast Cancer - A Register-Based Nested Case-Control Study (MK-0906-162/2003.021).
Sorafenib in Treating Patients With Metastatic Breast Cancer
FDG PET and DCE-MRI in Predicting Response to Treatment in Patients With Breast Cancer
Pilot Study of Paclitaxel Plus Pembrolizumab in Metastatic HER2-Negative Breast Cancer
Propranolol Hydrochloride in Treating Patients With Locally Recurrent or Metastatic Solid Tumors That Cannot Be Removed By Surgery
Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer
Tipifarnib and Combination Chemotherapy in Treating Patients With Stage II or Stage III Breast Cancer
Vaccine Therapy in Treating Patients Receiving Trastuzumab For HER2-Positive Stage IIIB-IV Breast Cancer
Vaccine Therapy in Combination With Rintatolimod and/or Sargramostim in Treating Patients With Stage II-IV HER2-Positive Breast Cancer
Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Hormone Therapy
Phase 1b/2 Trial Using Lapatinib, Everolimus and Capecitabine for Treatment of HER-2 Positive Breast Cancer With CNS Metastasis
Ixabepilone and Vorinostat in Treating Patients With Metastatic Breast Cancer
Omega-3 Fatty Acid in Treating Patients With Stage I-III Breast Cancer
18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy